Celltrion Takes Big Step On Xolair Biosimilar Journey

Phase I Trial For Omalizumab Candidate Began Last Year

Biosimilars major Celltrion has announced further progress on its biosimilar Xolair candidate, as it faces off against the likes of Glenmark to introduce global competition to Genentech/Novartis’ blockbuster cardiovascular biologic.

Growth
Celltrion has secured safety data from the interim results of Phase I clinical trials • Source: Shutterstock

Celltrion is making further strides on one of the significant ‘next wave’ biosimilar opportunities, kicking off a global Phase III trial for biosimilar Xolair (omalizumab) following approval for the firm’s investigational new drug application from Korea’s Ministry of Food and Drug Safety.

Phase III trials for the Korean firm’s CT-P39 biosimilar omalizumab candidate are scheduled to be conducted “through about 65 clinical...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

US Biosimilars

An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.

Amneal Kicks Off China Business With First Approval

Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

More from Generics Bulletin

GB-Business-Free-Podcast-The Secret to Walking More: It’s Not Counting Steps - Clone

 
• By 

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.